Compare INN & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INN | DRUG |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | United States |
| Employees | 78 | N/A |
| Industry | Real Estate Investment Trusts | Pharmaceuticals and Biotechnology |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 663.2M | 707.1M |
| IPO Year | N/A | 2020 |
| Metric | INN | DRUG |
|---|---|---|
| Price | $6.18 | $61.24 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $4.50 | ★ $129.25 |
| AVG Volume (30 Days) | ★ 1.5M | 396.0K |
| Earning Date | 04-30-2026 | 05-15-2026 |
| Dividend Yield | ★ 6.41% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.00 | N/A |
| Revenue Next Year | $1.96 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.98 | $23.18 |
| 52 Week High | $6.31 | $123.75 |
| Indicator | INN | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 66.01 | 28.07 |
| Support Level | $4.76 | $49.47 |
| Resistance Level | N/A | $61.76 |
| Average True Range (ATR) | 0.20 | 5.33 |
| MACD | 0.02 | -2.13 |
| Stochastic Oscillator | 82.64 | 5.52 |
Summit Hotel Properties Inc is a U.S.-based hotel investment company focusing on select-service hotels in the upscale and upper-midscale properties in the U.S. Substantially all of Summit's assets are held and operated by its Operating Partnership, Summit Hotel OP, LP, in which the company holds general and limited partnership interests. The firm has one segment in activities related to investing in real estate. Summit's revenue streams include Room and Other hotel operations revenue. Room comprises the majority of total revenues. The company's hotels are located in various markets, such as corporate offices, retail centers, airports, state capitols, convention centers, and leisure attractions. Summit's hotels operate under brands, including Marriott, Hilton, Hyatt, and Holiday Inn.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.